NCT02389218View on ClinicalTrials.gov

A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 3, 2015

Primary Completion Date

May 14, 2020

Study Completion Date

May 14, 2020

Conditions
Atrial Fibrillation
Interventions
DEVICE

single ablation (CryoBalloonAblation (CBA)

Cryoablation at entry, after randomization to this group

DRUG

sequential drug adjustment (propafenone, sotalol or flecainide)

Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone

Trial Locations (3)

1000

Brussels Heart Centre, Brussels

9000

Dept Cardiologie, Ghent

Unknown

Saint Luc, Brussels

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT02389218 - A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF | Biotech Hunter | Biotech Hunter